Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
IMUNON (NASDAQ: IMNN) has closed a private placement offering priced at-the-market under Nasdaq rules, securing $3.25 million in initial gross proceeds through the sale of 7,222,223 shares of common stock (or pre-funded warrants) at $0.45 per share. The deal includes short-term warrants to purchase up to 14,444,446 additional shares, which if fully exercised, could generate up to $6.5 million in additional gross proceeds.
The warrants will be exercisable at $0.45 per share following stockholder approval and will expire three years from that date. H.C. Wainwright & Co. served as the exclusive lead placement agent, with Brookline Capital Markets as co-placement agent. The company plans to use the proceeds for working capital and general corporate purposes.
IMUNON (NASDAQ: IMNN) has secured a private placement offering priced at-the-market, raising $3.25 million initially through the sale of 7,222,223 shares of common stock (or pre-funded warrants) at $0.45 per share. The deal includes short-term warrants to purchase up to 14,444,446 additional shares, which could generate up to $6.5 million in additional proceeds if fully exercised.
The warrants will be exercisable at $0.45 per share upon stockholder approval and will expire after three years. The offering, expected to close around May 27, 2025, is being managed by H.C. Wainwright & Co. as exclusive placement agent, with Brookline Capital Markets as financial advisor. The company plans to use the proceeds for working capital and general corporate purposes.
IMUNON (NASDAQ: IMNN) has announced groundbreaking results from its Phase 2 OVATION 2 Study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The study demonstrated a 13-month increase in median overall survival (46 vs. 33 months) and a 3-month improvement in progression-free survival (14.9 vs. 11.9 months) compared to standard care.
Notably, patients receiving PARP inhibitors alongside IMNN-001 showed exceptional results, with median overall survival not yet reached after 5+ years versus 37 months in the control group. The therapy was well-tolerated with no serious immune-related adverse events. Based on these promising results, IMUNON has initiated its pivotal Phase 3 OVATION 3 Study at two sites.
The findings will be presented at the 2025 ASCO Annual Meeting and published in Gynecologic Oncology.IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, has announced the withdrawal of its Form S-1 Registration Statement (No. 333-286403) with the SEC. The registration statement, originally filed on April 4, 2025, was withdrawn as the company has decided not to proceed with the planned public offering at this time. The statement had not been declared effective by the SEC, and no securities were sold in connection with the offering.